Versartis raises $20 mln in Series D financing
Versartis has closed $20 million in Series D financing. Sofinnova Ventures was the lead investor. Return backers Advent Venture Partners' Advent Life Sciences fund, Aisling Capital, Amunix Operating Inc., Index Ventures and New Leaf Venture Partners also participated in this round. In conjunction with the funding Sofinnova's general partner Dr. Srinivas Akkaraju will join Versartis board of directors. Based in Redwood City, Calif., Versartis is a biotechnology company focused on developing treatments for patients with endocrine disorders.
8 October 2013•4 mins read
